Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have ...

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

(MENAFN- GlobeNewsWire - Nasdaq) Explore the GLP-1R agonists market, uncovering new opportunities for repurposing beyond type 2 diabetes and obesity ... Novo Nordisk and Eli Lilly and potential ...

Drug manufacturers to focus on China and Japan, where penetration is low and innovation continues to emerge, Morgan Stanley ...

Eli Lilly & Co.’s obesity drug Zepbound helped people ... Although Novo was first to market with Wegovy and its sister drug ...

While Eli Lilly entered the market later, it is emerging as the ... "While Novo [Nordisk] took a commanding early lead in the obesity duopoly, they have ceded ground at a critical moment when ...

In December of last year, Eli Lilly directly compared the weight ... and that Zeb Bound is expected to soon seize the lead in the obesity market. There are analyses suggesting that Zeb Bound's ...

I believe orforglipron’s approval should finally lead to widespread and global availability of obesity medicines ... improve Eli Lilly’s leadership position in this market and these results ...

There is a small, exclusive group of companies with market caps above $1 trillion. Investors want to find companies that can ...

Novo Nordisk CEO Lars Jørgensen to step down amid increasing pressure from obesity drug competition and recent share price ...

While Eli Lilly entered the market later, it is emerging as the ... "While Novo [Nordisk] took a commanding early lead in the obesity duopoly, they have ceded ground at a critical moment when ...